Outlook Therapeutics Inc (OTLK)

[thermo]

Adverum (potential OTLK competitor) eyes disaster

Despite insisting that diabetic macular oedema and wet AMD had different causes, and that no cases of low eye pressure had been observed in wet AMD patients at any dose, Adverum has also abandoned ADVM-022’s pivotal trial, Optic, in this disease.

Adverum plans to start a new phase 2 trial in wet AMD next year, using lower doses. But SVB Leerink analysts feel that there is no viable path for ’022 in wet AMD, an indication with very low tolerance for safety events and numerous highly effective therapies.